Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Kaplan-Meier Approach01:24

Kaplan-Meier Approach

The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Characteristics and Outcomes of Finnish Patients with Waldenström Macroglobulinemia-A Real-World Study.

Clinical lymphoma, myeloma & leukemia·2026
Same author

Metastatic NSCLC patients in the real world in Finland.

Acta oncologica (Stockholm, Sweden)·2025
Same author

Real-world study on patient characteristics, treatment patterns and outcomes for treated patients with chronic lymphocytic leukemia during 2013-2022 in Finland.

Annals of hematology·2025
Same author

Valorisation scenarios of blended post-consumer textile waste with the focus on thermal processing strategies.

Waste management (New York, N.Y.)·2025
Same author

Ruxolitinib treatment outcomes in acute graft-versus-host disease (aGvHD) in a real-world setting in Finland.

Annals of hematology·2025
Same author

Evolution of treatment practices and outcomes in multiple myeloma during 2013-2022: a Finnish real world registry study.

Acta oncologica (Stockholm, Sweden)·2025
Same journal

Dapagliflozin in Patients with homozygous β-Thalassemia and Albuminuria.

Acta haematologica·2026
Same journal

Efficacy of second-generation FLT3 inhibitors in FLT3-mutated AML: A meta-analysis of randomized controlled trials.

Acta haematologica·2026
Same journal

Limited prognostic value of ELN classification and relevance of molecular ontogeny in acute myeloid leukemia post myeloproliferative neoplasms: a retrospective multicenter study.

Acta haematologica·2026
Same journal

Comparative efficacy of donor lymphocyte infusions in augmenting graft-versus-leukemia effect after allogeneic hematopoietic stem cell transplantation for patients with myeloid malignancies.

Acta haematologica·2026
Same journal

COVID-19 infection in patients with follicular lymphoma and related indolent B-cell lymphomas receiving anti-CD20 monoclonal antibody maintenance therapy.

Acta haematologica·2026
Same journal

Shared Care Offers an Effective Framework for Managing Tagraxofusp Treatment in Blastic Plasmacytoid Dendritic Cell Neoplasm.

Acta haematologica·2026
See all related articles

Related Experiment Video

Updated: Jun 14, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
10:46

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

Published on: December 9, 2015

Real-World Data on First Relapse in Multiple Myeloma: Treatment Patterns and Outcomes in Finland Using Automated Data

Johanna Vikkula, Kari Remes, Outi Laatikainen

    Acta Haematologica
    |June 12, 2026
    PubMed
    Summary
    This summary is machine-generated.

    New therapies improved outcomes for younger multiple myeloma (MM) patients at first relapse, but older MM patients saw little change in treatment or survival. Improved care is needed for elderly MM patients.

    More Related Videos

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Related Experiment Videos

    Last Updated: Jun 14, 2026

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
    10:46

    A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data

    Published on: December 9, 2015

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
    08:31

    Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

    Published on: October 17, 2025

    Area of Science:

    • Hematology
    • Oncology
    • Clinical Research

    Background:

    • Multiple myeloma (MM) is a hematologic malignancy.
    • Characterizing MM patients at first relapse is crucial for understanding treatment efficacy.
    • Outcomes for relapsed MM can vary significantly based on patient demographics and treatment advancements.

    Purpose of the Study:

    • To characterize multiple myeloma patients at their first relapse.
    • To examine and compare treatment outcomes in relapsed MM patients.
    • To identify disparities in care and outcomes between different age groups.

    Main Methods:

    • Retrospective registry-based study of relapsed MM patients (2013-2022) in Finland.
    • Patient data collected from multiple health registries.
    • Stratification by age (≤70 vs >70), index year, and time to first relapse.

    Main Results:

    • 286 relapsed MM patients met inclusion criteria.
    • Median overall survival from relapse was 32.4 months for younger (<70) vs 20.0 months for older (>70) patients.
    • Younger patients received newer therapies (CD38-based, pomalidomide) post-2018, unlike older patients.

    Conclusions:

    • Significant advancements in MM treatment are benefiting younger patients.
    • Older MM patients at first relapse have experienced limited changes in therapy and poorer outcomes.
    • There is an unmet need to enhance treatment strategies and care for elderly MM patients.